Abstract
Amyotrophic lateral sclerosis (ALS) is a multi-system disorder characterized by progressive muscular weakness and, in addition, cognitive/behavioral dysfunction in nearly 50% of patients. The mechanisms underlying risk for cognitive dysfunction, however, remain elusive. Using sparse canonical correlation analysis (sCCA), an unsupervised machine-learning technique, we observed that 26 single nucleotide polymorphisms collectively associate with baseline cognitive performance in 330 ALS patients from the multicenter Clinical Research in ALS and Related Disorders for Therapeutic Development consortium. We demonstrate that a polygenic risk score derived from sCCA relates to longitudinal cognitive decline in the same cohort, and also to in vivo cortical thinning (N=80) and post mortem burden of TDP-43 pathology in the middle frontal and motor cortices (N=55) in independent validation cohorts of patients with sporadic ALS. Our findings suggest that common genetic polymorphisms contribute to the manifestation of cognitive dysfunction and disease vulnerability in a polygenic manner in ALS.
Competing Interest Statement
The following authors declare the following competing interests: C. M. receives financial support from Biogen and has provided consulting for Axon Advisors. M.B. reports grants from National Institutes of Health, the ALS Association, The Muscular Dystrophy Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study; personal fees from Mitsubishi Tanabe Pharma, AveXis, and Genentech, outside the submitted work. In addition, M.B. has a provisional patent entitled ‘Determining Onset of Amyotrophic Lateral Sclerosis,’ and serves as a site investigator on clinical trials funded by Biogen and Orphazyme. All other authors declare no competing interests
Funding Statement
The CReATe consortium (U54NS092091) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. CReATe is funded through a collaboration between NCATS, and the NINDS. Additional research support was provided by the National Institutes of Health (NS106754, AG017586, NS092091). The genomics sequencing was funded by St. Jude Children’s Research Hospital American Lebanese Syrian Associated Charities (ALSAC) and the ALS Association (grants 17-LGCA-331 and 16-TACL-242)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
± Refer to Appendix for full CReATe Consortium author list.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.